Anicom Holdings, Inc. 1Q Earnings Preview

Insurance premium growth continues as policies in force surpass 1.4M; loss ratio and new business investment cost absorption are the key focus for 1Q

PublishedAugust 6, 2026 at 15:30 GMT+9

Summary

1Q FY2027/3 marks the first quarterly results of the second year under the Medium-Term Management Plan 2025-2027, making the primary checkpoint how much the expanded expenses and investment burden from the prior fiscal year can be absorbed by top-line growth. The company is guiding full-year recurring profit of JPY 5B (+41.1%), projecting a sharp V-shaped recovery from the prior year's earnings decline, with 1H cumulative recurring profit of JPY 4B (+90.6%) embedded in the plan. Policies in force surpassed 1.4M at end-May 2026, and top-line insurance premium growth remains solid, but whether the deteriorating trends in the prior year—E/I loss ratio of 62.2% (+1.6pt) and combined ratio of 95.0% (+2.1pt)—can reverse is the key to profit recovery. New businesses symbolizing the "Second Founding," including the veterinary hospital operations and health innovation segments, are now standalone reporting segments, making the narrowing of losses and the timeline for earnings contribution increasingly important in medium- to long-term valuation.

Key Points for Next Quarter

Key Points & Focus	Implications
Premium GrowthNet premiums written YoY growth	Critical to see if growth exceeds the prior year's full-year pace of +8.9%. With policies in force surpassing 1.4M, sustaining ~+10% in 1Q would increase confidence in the full-year plan (recurring income JPY 81B, +9.7%)
Loss Ratio ImprovementE/I loss ratio YoY trend	The prior year's full-year 62.2% (+1.6pt) showed a deteriorating trend; stabilization is a prerequisite for the company's guided profit recovery. Focus is on whether 1Q improves to the 61% range or below
Cost StructureGrowth rate of operating expenses and SG&A; expense ratio on earned premium basis	Prior year saw operating expenses +16.0% and expense ratio of 32.8% (+0.5pt), driven by costs related to policy portfolio migration from competitors. Watch for whether policy acquisition cost reduction efforts begin to materialize and drive the expense ratio lower
New BusinessesSegment P&L for veterinary hospital operations and health innovation	Combined loss of JPY 1,025M in the prior year. The key question is whether there are signs of loss narrowing from the ramp-up of the advanced medical facility "JARVIS Animal Medical Center Tokyo" and revenue expansion in health care products
Capital Policy & Shareholder ReturnsProgress on share buyback and path to 30% payout ratio	Monitor execution of the share buyback (up to JPY 1B, Jun-Jul), dividend forecast of JPY 13.50 (payout ratio 30.4%) aligns with mid-term plan targets. Assess contribution to ROE improvement (7.7% in prior year)
Combined RatioCombined ratio level and improvement trajectory	Prior year at 95.0% (+2.1pt) remained below 100% but trended unfavorably. Improvement to the 93% range in 1Q would suggest upside potential to the full-year earnings plan

Key Issues from Previous Results (FY2026/3 Full-Year Results)

In FY2026/3, recurring income reached a record high of JPY 73,846M (+9.1%), but recurring profit declined to JPY 3,543M (▲28.3%) due to rising insurance underwriting expenses (+11.2%) and a sharp increase in operating expenses (+16.0%). This reflected the first year of the Medium-Term Management Plan 2025-2027, which prioritized policy book expansion and new business investment. In the second year, FY2027/3, the focus shifts to executing a "quantity to quality" transition.

1. Progress on E/I Loss Ratio Improvement

Prior Year:
E/I loss ratio of 62.2% (+1.6pt YoY). Net claims paid of JPY 37,213M (+11.6%) outpaced premium growth (+8.9%)
This Year's Checkpoint:
Whether loss ratio improvement initiatives (promotion of preventive insurance, product design revisions, rate revision effects) are showing up in the numbers
Key Metrics:
Whether 1Q standalone E/I loss ratio falls below 61%. Whether growth in net claims paid converges to or below growth in net premiums written

The single most important metric governing pet insurance profitability. In the prior year, the loss ratio rose due to structural factors including rising average pet lifespans and veterinary cost inflation, weighing on earnings.

2. Moderation in Operating Expense Growth and Expense Ratio Improvement

Prior Year:
Expense ratio on earned premium basis of 32.8% (+0.5pt). Operating expense growth of +16.0% was ~1.8x the +8.9% premium growth rate
This Year's Checkpoint:
Whether the policy migration costs have run their course and whether policy acquisition cost reduction initiatives are taking effect, bringing operating expense growth in line with premium growth
Key Metrics:
Whether the expense ratio falls below 32%. Whether YoY growth in operating expenses and SG&A decelerates to single digits

In the prior year, operating expenses and SG&A surged to JPY 20,706M (+16.0%), far outpacing premium growth, driven by policy migration costs from competitors and new business investments.

3. Widening Losses in Veterinary Hospital Operations and Investment Recovery Outlook

Prior Year:
Segment loss of JPY 717M (vs. JPY 28M loss in the year prior, a significant widening). Capex on tangible and intangible fixed assets of JPY 1,896M, reflecting large-scale investment. Depreciation of JPY 405M (up sharply from JPY 90M in the year prior)
This Year's Checkpoint:
Ramp-up trajectory for "JARVIS Animal Medical Center Tokyo" in terms of utilization rate and clinical revenue. Timing for depreciation burden normalization and breakeven
Key Metrics:
Whether segment losses show a narrowing trend on a quarterly basis. Whether recurring income from external customers accelerates from the prior year's full-year pace of +10.7%

The veterinary hospital operations business, now a standalone segment from this fiscal year, saw widening losses as the company pursued hospital succession acquisitions and the launch of advanced medical facilities.

4. Monetization Timeline for Health Innovation Business

Prior Year:
Recurring income from external customers of JPY 573M (+65.8%). Segment loss of JPY 308M (vs. JPY 132M loss in the year prior, widening). Remains in the upfront investment phase
This Year's Checkpoint:
Whether accelerating revenue growth translates into loss narrowing. Whether cross-selling effects leveraging the insurance policyholder base are materializing
Key Metrics:
Whether quarterly revenue is on pace to exceed JPY 150M. Whether segment losses show an improving trend on a quarterly basis

The health innovation business, which develops and sells oral and gut care products, saw rapid revenue growth of +65.8% in the prior year, but losses also widened.

5. Progress on Capital Policy and Shareholder Returns

Prior Year:
Dividend of JPY 9.00 (payout ratio 30.2%). Share buyback of JPY 999M executed. ROE of 7.7% (down from 11.2% in the year prior). Additional buyback of up to JPY 1B approved as a subsequent event
This Year's Checkpoint:
Completion status of the share buyback, directional trajectory of ROE recovery accompanying earnings recovery, and initial disclosure of the new solvency regulation (ESR)
Key Metrics:
Whether the dividend forecast of JPY 13.50 (payout ratio 30.4%) is maintained or if there is room for an increase. Path to ROE recovery into the 8% range

The mid-term plan targets a ~30% payout ratio, and the prior year's actual result of 30.2% nearly achieved this. The company has also clearly stated its policy to opportunistically execute share buybacks.

Timely Disclosure & Industry Trends

2026/07/09
Doubutsu Kenpo policies in force surpass 1.4M — Policies in force surpassed 1.4M as of end-May 2026. The direct-settlement hospital network has expanded to 7,053 hospitals nationwide, a key KPI underpinning continued top-line insurance premium growth. Pet Insurance "Doubutsu Kenpo" Policies in Force Surpass 1.4 Million
2026/05/13
Announcement on co-evolution of "insurance" and "medicine" initiatives — Announced progress on prevention visualization leveraging gut microbiome and clinical data, and updates on the advanced veterinary care facility "JARVIS Animal Medical Center Tokyo." Notable as a concrete step in the preventive insurance strategy at the core of the mid-term plan. Initiatives on the Co-evolution of "Insurance" and "Medicine"
2026/05/12
Approval of share buyback (up to JPY 1B / 1M shares) — Acquisition period: June 1 – July 31, 2026. Materializes the shareholder return policy of dividends + buybacks under the mid-term plan. Equivalent to 1.3% of shares outstanding (excluding treasury shares). Notice Regarding Decision on Share Buyback

Previous Quarter Results (FY2026/3 Full-Year Results)

Anicom Holdings is the leading company in the pet insurance industry, commanding an overwhelming share of Japan's pet insurance market with approximately 1.39M policies in force. Its core subsidiary, Anicom Insurance, leverages a direct-settlement network (~7,000 hospitals nationwide) as a key competitive advantage. As the first year of the Medium-Term Management Plan 2025-2027 under the banner of becoming a "Preventive Insurance Group," the company accelerated upfront investment in veterinary hospital operations and health innovation businesses. Recurring income reached a new record high, but the bottom line declined due to a rising loss ratio and increased operating expenses.

Item	Amount	YoY	vs. Guidance	Remarks
Recurring Income	JPY 73,846M	+9.1%	-	Record high. Insurance underwriting income +8.9%, other recurring income +12.0%
Recurring Profit	JPY 3,543M	▲28.3%	-	Weighed down by insurance underwriting expenses +11.2% and operating expenses +16.0%
Net Income Before Tax	JPY 3,216M	▲32.3%	-	Impairment loss of JPY 228M recorded
Net Income Attributable to Owners of Parent Company	JPY 2,204M	▲32.1%	-	Effective tax rate 31.4%
EPS	JPY 29.77	▲29.1%	-	Weighted avg. shares outstanding: 74,039K (reflects buyback impact)

FY2027/3 Full-Year Guidance: Recurring income JPY 81B (+9.7%), recurring profit JPY 5B (+41.1%), net income JPY 3,250M (+47.4%), EPS JPY 44.43

Anicom Holdings, Inc.